January 5, 2026/
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has approved an update to the label for the long-acting contraceptive Depo-Provera (medroxyprogesterone acetate). The...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has approved an update to the label for the long-acting contraceptive Depo-Provera (medroxyprogesterone acetate). The...
This study investigated why reports of side effects (adverse drug reactions or ADRs) from a common HIV medication in Uganda are often incomplete, which hinders effective...
Hemodialysis vascular access is often termed the “lifeline” of patients with end-stage renal disease. However, due to frequent complications, it is also considered the “Achilles heel”...
